Eli Lilly and Company $LLY Shares Sold by OLD National Bancorp IN

OLD National Bancorp IN trimmed its position in Eli Lilly and Company (NYSE:LLY) by 0.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 613,291 shares of the company’s stock after selling 656 shares during the quarter. Eli Lilly and Company accounts for 9.5% of OLD National Bancorp IN’s holdings, making the stock its 2nd biggest holding. OLD National Bancorp IN owned 0.06% of Eli Lilly and Company worth $564,087,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of LLY. Balance Wealth LLC raised its holdings in shares of Eli Lilly and Company by 18.0% during the 1st quarter. Balance Wealth LLC now owns 223 shares of the company’s stock worth $205,000 after buying an additional 34 shares in the last quarter. Cottage Street Advisors LLC boosted its stake in Eli Lilly and Company by 10.9% in the first quarter. Cottage Street Advisors LLC now owns 2,040 shares of the company’s stock valued at $1,877,000 after buying an additional 200 shares in the last quarter. Louisiana State Employees Retirement System bought a new position in Eli Lilly and Company in the first quarter valued at about $37,159,000. Aegis Wealth Management Inc. raised its stake in Eli Lilly and Company by 0.7% during the first quarter. Aegis Wealth Management Inc. now owns 3,539 shares of the company’s stock worth $3,255,000 after acquiring an additional 23 shares in the last quarter. Finally, Hoge Financial Services LLC boosted its stake in shares of Eli Lilly and Company by 2.1% in the 1st quarter. Hoge Financial Services LLC now owns 526 shares of the company’s stock valued at $478,000 after purchasing an additional 11 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 7.0%

LLY opened at $1,206.51 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,215.76. The company has a fifty day moving average of $1,036.28 and a 200-day moving average of $1,020.95. The stock has a market cap of $1.14 trillion, a PE ratio of 42.86, a price-to-earnings-growth ratio of 1.32 and a beta of 0.53. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Analysts Set New Price Targets

A number of brokerages have recently commented on LLY. Berenberg Bank increased their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Leerink Partners lifted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research note on Thursday. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Rothschild & Co Redburn lifted their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,235.07.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.